Eli Lilly news and events in 2026
We're a medicine company turning science into healing to make life better for people around the world. " Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
- Dated updates
- 91
- Last event
- Sep 29, 2026
- Open rolesSnapshot Sep 29, 2026
- 246
- Latest SEC filing
- Aug 5, 2026
Overview
Eli Lilly by topic
110-K filing
28-K filings
246open roles
59+signals
53 in the last 90 days
- Glassdoor15+
- LinkedIn15+
- Patents9
- Podcasts8
- and 2 more sources
Latest events
Latest Eli Lilly events
Showing 10 of 27 events. The Signal API returns all of them.
Get them with one API call- In developmentLilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment...Eli Lilly and Company is studying its drug Orforglipron as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
- InvestmentEli Lilly Stock: Bet on OuraEli Lilly, along with Dragoneer Investment Group, is acting as a cornerstone investor in the IPO of sensor ring manufacturer Oura, signaling buying interest of up to $400 million.
- LaunchLilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsWith Chugai Pharmaceutical Co., Ltd.
- In developmentLLY Stock Rides Trump Spotlight: President Touts Eli Lilly’s $3.5B Factory As Weight-Loss Pill Plans Go GlobalEli Lilly and Company's experimental triple-hormone obesity drug, Retatrutide, is in Phase 3 trials and will be produced at its new Pennsylvania facility.
- Investment
- In developmentEli Lilly to invest in new plant that will generate 4,600 jobs: here are the available vacancies in TexasEli Lilly is developing Foundayo, a pill for weight control in overweight or obese adults, which will be mass-produced at its new Houston facility.
- LaunchEli Lilly and Company wins FDA pediatric Olumiant approval for severe alopeciaThe U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly's drug Olumiant, making it a treatment option for adolescents aged 12 and older with severe alopecia areata.
- RecognitionNovo is betting on its next chapter as Eli Lilly gains more ground in GLP-1sEli Lilly held about a 61% share in the U.S. GLP-1 market in the second quarter, compared to Novo's 39%.
- PartnershipWhy we like Starbucks’ latest turnaround move - plus, two more wins for Eli Lilly$3.4B · With InnoCare Pharma
- EarningsFDA approval for Lilly’s weekly insulin Onswik, shares dipEli Lilly reported net income of $7.1bn for the second quarter of 2026.
Showing 10 of 27 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Eli Lilly with the Signal API
One POST /v1/companies/enrich call with lilly.com returns every signal type for Eli Lilly, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","limit":20}'Same industry
Companies related to Eli Lilly
Eli Lilly questions
What is the latest news on Eli Lilly?
What is going on with Eli Lilly?
Has Eli Lilly announced any acquisitions?
What else does Autobound track for Eli Lilly?
Is Eli Lilly hiring right now?
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .